Display options
Cite
Koenders PG, Beex LV, Kloppenborg PW, et al. Human breast cancer: survival from first metastasis. Breast Cancer Study Group. Breast Cancer Res Treat. 1992;21(3):173-80doi: 10.1007/BF01975000.
Koenders, P. G., Beex, L. V., Kloppenborg, P. W., Smals, A. G., & Benraad, T. J. (1992). Human breast cancer: survival from first metastasis. Breast Cancer Study Group. Breast cancer research and treatment, 21(3), 173-80. https://doi.org/10.1007/BF01975000
Koenders, P G, et al. "Human breast cancer: survival from first metastasis. Breast Cancer Study Group." Breast cancer research and treatment vol. 21,3 (1992): 173-80. doi: https://doi.org/10.1007/BF01975000
Koenders PG, Beex LV, Kloppenborg PW, Smals AG, Benraad TJ. Human breast cancer: survival from first metastasis. Breast Cancer Study Group. Breast Cancer Res Treat. 1992;21(3):173-80. doi: 10.1007/BF01975000. PMID: 1515652.
Copy Download .nbib Format: NLM
Share it on

Breast Cancer Res Treat. 1992;21(3):173-80. doi: 10.1007/BF01975000.

Human breast cancer: survival from first metastasis. Breast Cancer Study Group.

Breast cancer research and treatment

P G Koenders, L V Beex, P W Kloppenborg, A G Smals, T J Benraad

Affiliations

  1. Department of Medicine, University Hospital Nijmegen, The Netherlands.

PMID: 1515652 DOI: 10.1007/BF01975000

Abstract

Survival from the detection of first metastasis (SAM) was analyzed in a single center series of 258 patients with advanced breast cancer. During the 15 year period covered by this study 230 patients died, 215 of their disease. The overall median SAM was 28 months. Univariate analysis of SAM stratified by first dominant site of metastasis, estrogen receptor status (ER), progesterone receptor status (PgR), tumor size, axillary lymph node status, patient age, menopausal status, and disease-free interval (DFI) showed the first dominant site of metastasis, ER, PgR, and axillary lymph node status to be significantly associated with SAM. Patients with visceral metastasis as first dominant site of metastasis had significantly shorter survival than those with either bone or soft tissue metastasis, median SAM 16 vs. 34 vs. 41 months respectively (P less than 0.001). SAM also differed according to the steroid hormone receptor status of the primary tumor: median SAM 34 and 33 months for patients with ER-positive or patients with PgR-positive tumors against 14 months for patients with ER-negative or with PgR-negative tumors (P less than 0.001). Patients with axillary lymph node involvement at primary disease had a shorter SAM than those without, median SAM 24 vs. 35 months (P = 0.006). No association between SAM and either tumor size, patient age, menopausal status, or DFI could be observed. Multivariate analysis including first dominant site of metastasis, ER, PgR, and axillary lymph node status showed the first dominant site of metastasis, ER, and axillary lymph node status to be independently associated with SAM.

Similar articles

Cited by

References

  1. Lancet. 1984 Mar 17;1(8377):588-91 - PubMed
  2. Br J Cancer. 1989 Aug;60(2):252-7 - PubMed
  3. Br J Cancer. 1981 Sep;44(3):456-9 - PubMed
  4. Br J Cancer. 1990 Jul;62(1):142-6 - PubMed
  5. Eur J Cancer. 1980 Nov;16(11):1513-5 - PubMed
  6. Cancer Res. 1988 Oct 1;48(19):5565-9 - PubMed
  7. Cancer. 1969 Nov;24(5):861-9 - PubMed
  8. J Clin Oncol. 1987 Jan;5(1):55-61 - PubMed
  9. Cancer. 1988 Feb 15;61(4):758-68 - PubMed
  10. Br J Cancer. 1985 Feb;51(2):263-70 - PubMed
  11. Cancer. 1990 Sep 15;66(6):1165-7 - PubMed
  12. Eur J Cancer Clin Oncol. 1987 Apr;23(4):443-8 - PubMed
  13. Cancer. 1954 Jan;7(1):29-46 - PubMed
  14. Breast Cancer Res Treat. 1991 Mar;18(1):27-32 - PubMed
  15. Eur J Cancer. 1981 Apr;17(4):449-53 - PubMed
  16. Cancer. 1979 Aug;44(2):671-5 - PubMed
  17. Eur J Cancer Clin Oncol. 1982 Oct;18(10):937-43 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources